Parthenon Therapeutics Announces Publication in Journal for ImmunoTherapy of Cancer on the Role of PRTH-101 Inhibiting DDR1 in Immune Excluded Tumors

Parthenon Therapeutics has announced the publication of its research in the Journal for ImmunoTherapy of Cancer, which shows how PRTH-101 can inhibit collagen receptor discoid in domain receptor-1 (DDR1)-expressing cancer cells and reverse immune exclusion. The study was conducted with George Washington University and The University of Texas Health Center at Houston. Parthenon recently initiated..